BRIEF—Tevogen Bio appoints CSO and R&D head

US late-stage clinical biotech Tevogen Bio has announced the appointment of preeminent oncologist Neal Flomenberg as chief scientific officer (CSO) and global head of research and development.

Dr Flomenberg will lead the company’s diverse and rapidly advancing research and development initiatives of its highly adaptable precision T cell product pipeline in oncology, neurology, and virology.

Most recently, Dr Flomenberg served as professor and chairman of the Department of Medical Oncology and Deputy Director of Sidney Kimmel Cancer Center of Thomas Jefferson University & Hospital. Under his leadership, Jefferson’s Department of Medical Oncology more than tripled in size, established a nationally recognized senior adult oncology program as well as an embedded Supportive Medicine and Survivorship Program. At Jefferson, Dr Flomenberg also served as director of the Hematologic Malignancies, Blood and Marrow Transplantation (BMT) program.

In his new capacity at Tevogen, Dr Flomenberg will serve as member of the executive team and lead company’s ambitious R&D initiatives, allowing for further advancement of its next generation precision T cell technology platforms. Dr Flomenberg and his leadership team will operate out of Tevogen’s R&D Center located in Philadelphia’s Wanamaker building.